title: Combined evaluation of the Glasgow prognostic score and carcinoembryonic antigen concentration prior to hepatectomy predicts postoperative outcomes in patients with liver metastasis from colorectal cancer.
abstract: OBJECTIVE
  Little is known about the ability of the inflammation-based Glasgow prognostic score (GPS).
  
  
  METHODS
  106 patients who underwent curative resection for colorectal liver metastasis (CRLM) were analyzed. Patients with an elevated Creactive protein concentration (>10 mg/L) and hypoalbuminemia (<35 g/L) at admission were assigned a GPS 2, those with only 1 of these biochemical abnormalities were assigned a GPS 1, and those without either abnormality were assigned a GPS 0.
  
  
  RESULTS
  Multivariate analysis showed that 2 variables, carcinoembryonic antigen (CEA) concentration > 30 ng/mL and a GPS 1 or 2, were independently prognostic of survival. Patients were classified into 3 groups on the basis of these 2 variables. Patients with GPS 1 or 2 and CEA concentration > 30 ng/mL were assigned a new score of 2, those with either 1 factor were assigned a new score of 1, and those with neither factors were assigned a new score of 0. The 5-year overall survival rates of new scores of 0, 1, 2 were 71.5%, 31.6%, and 0%, respectively (P < 0.0001).
  
  
  CONCLUSIONS
  This simple staging system may be able to identify a subgroup of patients who are eligible for curative resection but show poor prognosis.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Masayo
authors.initials: M
authors.lastname: Kawakamil
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Hara
authors.forename: Sadaaki
authors.initials: S
authors.lastname: Shioiri
authors.forename: Masamichi
authors.initials: M
authors.lastname: Yasuno
authors.forename: Masanori
authors.initials: M
authors.lastname: Teruya
authors.forename: Michio
authors.initials: M
authors.lastname: Kaminishi
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D015897:Comorbidity; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D034141:Hypoalbuminemia / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging / Q000379:methods*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis*; D000075462:Serum Albumin, Human; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C422455:ALB protein, human; D002272:Carcinoembryonic Antigen; D012709:Serum Albumin; D002097:C-Reactive Protein; D000075462:Serum Albumin, Human